#IDSA AMR Updates 2023
#IDtwitter
#Medtwitter
Updates in ESBL E
To avoid piptaz in non UTI
To avoid Cefepime
No role of Cephamycins
No role of Ceftalazone - Tazobactam
@CidsIndia
@idcon2022 @id_cure
@IDstewardship
Updates in AmpC
Explained well about How to choose Antibiotics in AmpC -
Updates in CRE -
Explicitly mentions TOC for NDM, OXA, KPC & while awaiting reports.
No role of Tetracycline derivatives in UTI/ BSI
Updates in Pseudo
TOC for MDR Pseudo
TOC for MBL - No added benefit of Ceftazidime -avibactam+Aztreonam vs Aztreonam alone
Combination therapy in DTR Pseudo-Don't use Polymxin+Aminoglycosides -use Newer BL-BLI+Tobramycin if tobra is S, if R use Newer BL-BLI+ Polymyxin
Updates in CRAB
CRAB therapy -Sulbactam + Mino>Tige , or Sulbactam + Polymyxin B, Mero + Poly B not to be used
If using Ampicillin - Sulbactam - panel suggest *against* the use of Meropenem in the combination
Stenotrophomonas updates
Combination only - no role of single agent
Ceftazidime -avibactam + Aztreonam if clinical instability, intolerance
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.